Furthermore, radiogenomics can help identify gene signatures linked to tumor behavior by employing radiopharmaceuticals beyond [18F]FDG and PSMA ligands, such as FAPI, PD-1, and PD-L1 imaging. This evidence concerns the gene FOLH1 and neoplasm.